MIRANDA IACOPELLI: Open Payments
NPI 1144701228 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,512 in 71 payments from 30 companies in 2025. Trend: 2023 $1,757 · 2024 $1,510 · 2025 $1,512
Food & beverage: $1,512
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $172 |
| Merck Sharp & Dohme LLC | 5 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $136 |
| BeOne Medicines USA, Inc. | 4 | $97 |
| Eisai Inc. | 3 | $82 |
| GENZYME CORPORATION | 3 | $77 |
| Incyte Corporation | 3 | $71 |
| Celgene Corporation | 3 | $66 |
| Lilly USA, LLC | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
Products named: KISQALI, FRUZAQLA, KEYTRUDA, BRUKINSA, Lenvima, SARCLISA, REBLOZYL, OJJAARA.
Industry payments across MI — which companies pay providers there.
